These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8163718)

  • 1. Pharmacokinetics and pharmacodynamics of intravenous OPC-18790 in humans: a novel nonglycosidic inotropic agent.
    Ohnishi A; Toyoki T; Ohno T; Takeshige Y; Fujita T; Kodama K; Mishima M; Hirayama A; Kitani M; Miyamoto G
    J Clin Pharmacol; 1994 Feb; 34(2):176-83. PubMed ID: 8163718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of a novel inotropic agent (OPC-18790) on systolic and diastolic function in patients with severe heart failure.
    Hoit BD; Burwig S; Eppert D; Bhat G; Walsh RA
    Am Heart J; 1994 Dec; 128(6 Pt 1):1156-63. PubMed ID: 7985596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic profile of OPC-8212 in humans: a new, nonglycosidic, inotropic agent.
    Ohnishi A; Ishizaki T
    J Clin Pharmacol; 1988 Aug; 28(8):719-26. PubMed ID: 3216039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of a new cardiotonic vasodilator agent, 349U85, in normal subjects.
    Clifton GD; Harrison MR; Wermeling DP; Long RA; Fleck RJ; Rolleri RL; Weller S; Brown AR; Welch RM
    Clin Pharmacol Ther; 1994 Jan; 55(1):55-63. PubMed ID: 8299318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute cardiovascular effects of OPC-18790 in patients with congestive heart failure. Time- and dose-dependence analysis based on pressure-volume relations.
    Feldman MD; Pak PH; Wu CC; Haber HL; Heesch CM; Bergin JD; Powers ER; Cowart TD; Johnson W; Feldman AM; Kass DA
    Circulation; 1996 Feb; 93(3):474-83. PubMed ID: 8565164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positive inotropic and negative chronotropic effects of OPC-8490, a newly developed cardiotonic, in isolated, blood-perfused canine heart preparations.
    Furukawa Y; Akahane K; Haniuda M; Chiba S
    Jpn Heart J; 1989 May; 30(3):387-98. PubMed ID: 2552190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of simendan, a novel calcium sensitizer, in healthy volunteers.
    Lilleberg J; Antila S; Karlsson M; Nieminen MS; Pentkäinen PJ
    Clin Pharmacol Ther; 1994 Nov; 56(5):554-63. PubMed ID: 7955820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel inotropic vasodilator, OPC-18790, reduces myocardial oxygen consumption and improves mechanical efficiency with congestive heart failure.
    Kanda H; Yokota M; Ishihara H; Nagata K; Kato R; Sobue T
    Am Heart J; 1996 Aug; 132(2 Pt 1):361-8. PubMed ID: 8701899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haemodynamic dose-efficacy of levosimendan in healthy volunteers.
    Lilleberg J; Sundberg S; Häyhä M; Akkila J; Nieminen MS
    Eur J Clin Pharmacol; 1994; 47(3):267-74. PubMed ID: 7867680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct myocardial effects of OPC-18790 in human heart failure: beneficial effects on contractile and diastolic function demonstrated by intracoronary infusion with pressure-volume analysis.
    MacGowan GA; Haber HL; Cowart TD; Tedesco C; Wu C; Feldman MD
    J Am Coll Cardiol; 1998 May; 31(6):1344-51. PubMed ID: 9581731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of dobutamine and OPC-18790 on diastolic chamber stiffness in patients with idiopathic dilated cardiomyopathy.
    Machii T; Yokota M; Nagata K; Ishihara H; Iwase M; Sobue T
    J Cardiovasc Pharmacol; 1997 Feb; 29(2):265-72. PubMed ID: 9057077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clevidipine: a review of its use in the management of acute hypertension.
    Deeks ED; Keating GM; Keam SJ
    Am J Cardiovasc Drugs; 2009; 9(2):117-34. PubMed ID: 19331440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, safety, and pharmacologic effects of OPC-21268, a nonpeptide orally active vasopressin V1 receptor antagonist, in humans.
    Ohnishi A; Ko Y; Fujihara H; Miyamoto G; Okada K; Odomi M
    J Clin Pharmacol; 1993 Mar; 33(3):230-8. PubMed ID: 8385161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiotonic activity of a new inotropic agent, 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (OPC-8212), in the dog with and without beta-blocker and Ca++-antagonist pretreatment.
    Hori M; Inoue M; Tamai J; Koretsune Y; Kitakaze M; Iwai K; Ito H; Kitabatake A; Kamada T
    Jpn Circ J; 1986 Jan; 50(1):37-44. PubMed ID: 3702034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of OPC-18790, a new positive inotropic agent, on canine ventricular arrhythmias.
    Wu Z; Awaji T; Abe H; Motomura S; Hashimoto K
    Jpn J Pharmacol; 1993 Nov; 63(3):399-404. PubMed ID: 8107332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites.
    Puttonen J; Kantele S; Kivikko M; Häkkinen S; Harjola VP; Koskinen P; Pentikäinen PJ
    Clin Pharmacokinet; 2007; 46(3):235-46. PubMed ID: 17328582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure.
    Sabbah HN; Imai M; Cowart D; Amato A; Carminati P; Gheorghiade M
    Am J Cardiol; 2007 Jan; 99(2A):41A-46A. PubMed ID: 17239704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of OPC-18790, a new positive inotropic agent, on energetics in the ischaemic canine heart: a 31P-MRS study.
    Ishikawa M; Mori T; Itoh S; Fujiki H; Koga K; Tominaga M; Yabuuchi Y
    Cardiovasc Res; 1995 Aug; 30(2):299-306. PubMed ID: 7585818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation on SCH00013, a novel cardiotonic agent with Ca++ sensitizing action. 2nd communication: in vivo cardiovascular effects and bioavailability in dogs.
    Yoshimura A; Koide Y; Yoshioka K; Hino M; Sugawara H; Sakato M; Endoh M
    Arzneimittelforschung; 1999 May; 49(5):407-11. PubMed ID: 10367102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing.
    Chu KM; Shieh SM; Hu OY
    Clin Pharmacol Ther; 1995 Jun; 57(6):610-21. PubMed ID: 7781260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.